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introduction: Vaccine responses are often reduced in the elderly, leaving part of the 
elderly population vulnerable to infectious diseases. Timely vaccination may offer a 
solution for strengthening memory immunity before reaching old age, which classifies 
middle-aged persons as a target age group for vaccine interventions. However,  knowledge 
regarding the immunogenicity of primary immunizations in middle-aged adults is lacking. 
We determined the immunogenicity of a primary meningococcal vaccine towards which 
no or (very) low pre-vaccination immunity exists in middle-aged adults (NTR4636).
Methods: A vaccine containing multiple meningococcal groups (tetravalent) conjugated 
to tetanus toxoid (MenACWY-TT) was administered to middle-aged adults (50–65 years 
of age, N = 204) in a phase IV single-center and open-label study. Blood samples were 
taken pre-, 7 days, 28 days, and 1 year post-vaccination. Functional antibody titers were 
measured with the serum bactericidal assay (SBA). Meningococcal- and tetanus-specific 
antibody responses were determined with a fluorescent bead-based multiplex immuno-
assay. A bi-exponential decay model was used to estimate long-term protection.
results: In the majority of the participants, the meningococcal vaccine clearly induced 
naïve responses to meningococci W (MenW) and meningococci Y (MenY) as compared 
to a booster response to meningococci C (MenC). After 28 days, 94, 99, and 97% of the 
participants possessed a protective SBA titer for MenC, MenW, and MenY, respectively, 
which was maintained in 76, 94, and 86% 1 year post-vaccination. At this 1-year time 
point, significantly lower SBA titers were found in participants without a pre-vaccination 
SBA titer. Overall, protective antibody titers were predicted to persist after 10 years in 
40–60% of the participants. The SBA titers correlated well with the meningococcal-spe-
cific IgM responses, especially for MenW and MenY. Interestingly, these IgM responses 
were negatively correlated with age.
conclusion: Primary immunization with a tetravalent meningococcal vaccine was 
highly immunogenic in middle-aged adults, inducing protective antibody titers in the vast 
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majority of the participants lasting for at least 1 year. The age-related decrease in highly 
functional IgM responses argues in favor of vaccination against de novo antigens before 
reaching old age and, hence, middle-aged persons are an age group of interest for future 
vaccine interventions to protect the aging population.
Keywords: immunosenescence, aging, middle-aged, primary immunization, igM, de novo antigens, meningococci
inTrODUcTiOn
The world population is rapidly aging. Worldwide predictions 
indicate that by the year 2050, the number of persons above 
60 years of age is more than doubled as compared to 2015, with 
the numbers of persons above 80  years of age, the so-called 
“oldest-olds,” increasing even faster (1). Population aging has 
major medical implications, as with age vulnerability to both 
chronic and infectious diseases increases. Due to increased num-
bers of susceptible elderly, the population herd immunity against 
infectious diseases may diminish (2, 3). Therefore, prevention of 
infectious diseases by immunization of the elderly is a prerequi-
site for establishing healthy aging (4, 5).
With age, reduced thymic output of naïve T-cells and reduced 
bone marrow B-cell niches are observed, causing compositional 
changes in both compartments of the adaptive immune system 
(5–8). These alterations affect both the cellular and the humoral 
immune responses to vaccines (7, 9). For example, the elderly show 
reduced T-cell responses after varicella zoster vaccination (10), 
as well as reduced functional antibody responses after seasonal 
influenza, pneumococcal, and yellow fever vaccination (11–15). 
Larger effects of immunological aging are expected for de novo 
immune responses, as compared with the above-mentioned recall 
responses (hereafter called booster responses), due to reduced 
numbers of naïve cells (2, 3, 16).
Timely vaccination before reaching old age may offer a solu-
tion for circumventing these deleterious effects (2, 11). Due to the 
early appearance of the first signs of immune aging by the age of 
50 (6), it has been suggested that immunization against new anti-
gens most probably will have to be implemented at middle-age 
(2). However, the immunological fitness of middle-aged persons 
is largely unknown.
We determined the immunogenicity of a primary meningo-
coccal vaccine in middle-aged adults (50–65 years of age). Due 
to herd immunity in the population after the mass vaccination 
campaign (in children 1–19  years of age) in 2002, circulation 
of meningococci C (MenC) is virtually non-existing, resulting 
in reduced memory immunity in the elderly population (17). 
Moreover, historical circulation of meningococci W (MenW) 
and meningococci Y (MenY) in the Netherlands has been very 
low, indicating that the meningococcal vaccination will most 
probably induce naïve type responses in older adults (17). Due to 
this expected low pre-vaccination immunity, the meningococcal 
vaccine was used as a model antigen to study primary vaccine 
responses in middle-aged adults.
Nowadays, next to young infants and adolescents, an increase 
of meningococcal cases is observed in persons over 65 years of 
age, which are mainly caused by MenW and MenY (18, 19). Also, 
the highest meningococcal case fatality rate has been reported in 
this age group, which may be due to underlying comorbidities 
(18–20). In addition, the currently ongoing MenW outbreak in 
the Netherlands is exactly following the course of the outbreak 
in the UK with 2 years delay, in which a large proportion of the 
invasive meningococcal disease cases was observed in persons 
above 65 years of age (21, 22). This vulnerability for meningococ-
cal disease in the elderly population may further increase due to 
population aging (17, 23).
Until now, few studies investigated the immunogenicity of 
meningococcal vaccination in older adults (23, 24). In addition, 
immunogenicity studies were mostly performed in a historically 
naturally primed population. Here, we investigated the immu-
nogenicity of a primary MenACWY-tetanus toxoid (TT) vac-
cination in an expected “immunologically naïve” middle-aged 
(50–65 years old) population. Moreover, a bi-exponential decay 
model was used to estimate the long-term protection induced by 
the vaccination in this middle-aged target group.
MaTerials anD MeThODs
study Design and Participants
Within this phase IV single-center and open-label study, invita-
tions were sent to middle-aged adults (between 50 and 65 years 
of age) in Amersfoort, a city in the middle of the Netherlands, 
during August/September 2014. The Dutch community-based 
administration was used to send the invitations. Potential 
participants were excluded based on the following criteria: 
antibiotic use or fever (>38°C) within the last 14 days, serious 
diseases demanding immune suppressive medical treatment 
within the last 3  months, a known or suspected immune 
deficiency, a blood coagulation disorder, a neurologic disorder, 
administration of blood products in the past 6 months, serious 
surgery within the last 3 months, the use of hormone supple-
mentation, pregnancy, a suspected allergy toward the vaccine 
components, history of serious adverse events after previous 
vaccinations, a previous meningococcal vaccination, a previous 
meningococcal episode, a tetanus vaccination within the last 
5  years, and any vaccination in the month before enrollment. 
Written informed consent was obtained from all participants 
prior to enrollment and all procedures were in accordance with 
the Declaration of Helsinki. The medical ethical committee: 
Medical Research Ethics Committees United (MEC-U) approved 
the study and the study was registered at the Dutch trial register 
(NTR4636).
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Vaccination and Blood sampling
A pre-vaccination blood sample was taken from all participants. 
Subsequently, all participants received the tetravalent menin-
gococcal vaccine conjugated to TT (MenACWY-TT, Nimenrix, 
GlaxoSmithKline) by intramuscular administration. Blood 
samples were taken 7 days, 28 days, and 1 year post-vaccination. 
Serum samples were collected using serum clotting tubes 
(BD Biosciences) and were stored at −20°C until further use. All 
participants were sampled during evening hours. In addition, all 
participants filled in a short health questionnaire during the first 
appointment.
serological analysis
IgG and IgG subclass concentrations specific for the polysac-
charides of the meningococcal groups C, W, and Y (MenCWY), 
and TT were determined by the fluorescent-bead-based-
multiplex immuno assay as previously described (25–28). An 
internationally accepted TT-specific IgG concentration of 
0.01 IU/ml was used as protection level (29). A similar method 
was used to determine the MenCWY-specific IgM concentra-
tions, with the modification of using a donkey anti-human IgM 
RPE conjugate (Fc5μ specific, Jackson ImmunoResearch).
MenA-specific measurements were left out of the analysis due 
to interference of varying levels of cross-reacting antibodies to 
MenA, present in these older age cohorts, in the immunoassay. 
Moreover, the analysis of MenCWY-specific responses is per-
ceived sufficient to answer our primary research question in this 
study.
The MenCWY-specific protective antibody titers were 
determined with the serum bactericidal antibody assay using 
baby rabbit complement (rSBA) (Pelfreez, LOT#13035EL), as 
described previously (30, 31). The MenC, MenW, and MenY 
strains used in the rSBA were C11, MP01240070, and S-1975, 
respectively, kindly donated by Prof. Dr. Ray Borrow from the 
Vaccine Evaluation Unit at Manchester (PHE). The bactericidal 
titer was expressed as the reciprocal of the highest serum 
dilution yielding ≥50% killing after 60 min of incubation. The 
internationally accepted correlate of protection used was an 
rSBA titer of ≥8 for all groups, whereas a titer of ≥128 was 
used as a more conservative measure for long-term protection 
(31, 32). Participants with an rSBA titer below detection level 
(rSBA seronegative) were assigned an rSBA titer of two for 
statistical purposes. A representative group of 100 persons was 
selected for the functional rSBA analysis, based on varying IgG 
levels from low to high concentrations, for all three meningococ-
cal groups. For MenW and MenY, the same selection of partici-
pants was used. This selection had an overlap of 71 participants 
with the selection for MenC.
Gullsorb reagent human IgG (Meridian Biosciences™) was 
used for IgG depletion and goat-Anti-human IgM (μ-chain 
specific)-Agarose antibody beads (Sigma Aldrich) for IgM deple-
tion in the serum samples.
statistics
Normal distribution of the data was checked prior to each 
analysis and only cases with samples available at all time points 
were included in the analysis. Geometric mean concentrations 
(GMCs) with 95% confidence intervals [95% CI] were calcu-
lated for the MenCWY-PS- and TT-specific IgG responses, 
as well as the MenCWY-PS-specific IgG subclass and IgM 
responses. MenCWY-PS-specific IgG and IgM concentrations 
were log transformed, after which the repeated measurements 
ANOVA was used to analyze the post-vaccination response. 
rSBA geometric mean titers (GMTs) with the corresponding 
95% CI were calculated. Proportions and 95% CI of participants 
with an rSBA ≥8 and ≥128 were calculated with the Wilson/
Brown test. The proportion of participants with an rSBA ≥8 
and ≥128 were compared between participants with and 
without a pre-vaccination serum bactericidal assay (SBA) titer 
with the Chi-squared test, whereas differences in GMTs were 
analyzed with the Mann–Whitney U test. Differences in IgG 
ratios between the meningococcal groups were analyzed with 
the Mann–Whitney U test preceded by the Kruskal–Wallis test 
and corrected for multiple comparisons with the Bonferroni 
correction.
Correlations between the rSBA titers and the IgG and IgM 
responses 28 days and 1 year post-vaccination were determined 
using the Spearman’s rho correlation test. Graphpad Prism V7 
and SPSS V22.0 were used for the statistical analysis. A p-value 
<0.05 was considered statistically significant.
Bi-exponential Decay Model
To study the duration of protection, we used a Bayesian approach 
with a multilevel longitudinal model to statistically predict 
the dynamics of antibody concentrations (33). We performed 
Markov-chain Monte Carlo simulations to find the appropriate 
joint distribution of parameters which best could adjust the 
model to the measured rSBA titer datasets for MenC, MenW, 
and MenY. Assuming a simple exponential decay after reaching 
the time to peak (t1) would underestimate the persistence of 
protection (33–35). Therefore, we modeled the rSBA titer decay 
assuming that it follows a bi-exponential decay curve of the form:
 y( )t t y e fe f
t t t t> = +( ) +− −( ) − −( )1 1 1 1 2 1 1α α / ( ) 
where y1 is the peak antibody concentration level, α1 and α2 are 
the respective decay rates of each exponential component, and f 
regulates the contribution of the exponential components.
The initial raise of antibody levels was assumed to be exponen-
tial until the time to peak t1. Per individual, the three measured 
antibody levels were used to fit the multilevel model with their 
respective time point. The time to peak (t1) in the model was 
set to follow a lognormal distribution with a mean of 12  days 
(SD 8.5 days). The long-term antibody persistence was described 
using the decay curves predicted by the models. To assess the 
duration of protection, we focused on the predicted percentages 
of participants that possessed an rSBA titer >8 and >128, for any 
given time up to 10 years post-vaccination.
resUlTs
study Population
A total of 204 middle-aged adults (mean age: 57.7 years; range 
50–65  years; 52% males) participated in the study (Figure  1). 
FigUre 1 | Participant flow chart.
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All participants received the MenACWY-TT vaccine. Overall, 194 
participants (95.1%) completed the study, with blood drawings 
before vaccination and at 7, 28 days, and 1 year post-vaccination. 
Additional baseline participant characteristics are presented in 
Table S1 in Supplementary Material.
igg responses reflect general naïve and 
Booster responses after MenacWY-TT 
Vaccination in Middle-aged adults
At first, longitudinal MenCWY and TT-specific IgG responses 
were investigated (Figures 2A–C; Figure S1 in Supplementary 
Material). Pre-vaccination, low IgG levels were observed for 
the different meningococcal groups. Seven days post-vaccination, 
IgG responses were enhanced for all three groups (Figures 2A–
C), although a higher increase in the IgG response (ratio day 
7/pre) was observed for MenC as compared to MenW and 
MenY (Table  1). This was also reflected in the number of 
persons with an IgG fold increase above four at day 7, which 
was 58.8, 20.1, and 22.5% for MenC, MenW, and MenY, respec-
tively (Table  1). Moreover, compared to the other groups, 
a significant higher increase in MenC-specific IgG was observed 
28  days post-vaccination (ratio day 28/pre) (Table  1). Taken 
together, these results are suggestive of a booster response 
to MenC as compared to a naïve response in the majority of 
the participants to MenW and MenY. Nonetheless, based on 
the IgG response 7  days post-vaccination, a few participants 
also showed booster responses for MenW and MenY as well 
as naïve responses to MenC. In addition, MenC-specific IgG 
concentrations showed a larger decay from 28 days to 1 year 
(ratio day 28/1 year) post-vaccination than seen for MenW and 
MenY IgG levels, resulting in comparable IgG GMCs 1  year 
post-vaccination for all three groups (Table 1). Notably, these 
IgG concentrations were still significantly enhanced compared 
with pre-vaccination levels (Figures 2A–C). The TT conjugate 
clearly induced a booster response in the participants, since 
71.6% of the persons showed highly significant increases in IgG 
concentrations 7 days post-vaccination (Table 1). In the major-
ity of the middle-aged persons, pre-vaccination TT-specific IgG 
concentrations were above the protection level of 0.01 IU/ml 
and these were significantly enhanced up to 1  year post-
vaccination (Table  1; Figure S1 in Supplementary Material). 
Within this cohort, we did not observe any effects of age, 
gender, and CMV seropositivity on the IgG responses (Table 
S2 in Supplementary Material).
Remarkably, a robust IgM response was observed for all 
meningococcal groups and these IgM levels were still enhanced 
1 year post-vaccination (Figures 2D–F). A significant negative 
correlation was found between the IgM responses and age for 
MenC and MenW, whereas a negative trend was observed for 
MenY (Table 2). However, the low predictive value of the model 
(R2 model) indicates that age and pre-existing IgM concentrations 
were not the major factors predicting the IgM concentrations 
post-vaccination.
The Meningococcal groups induced 
Protective rsBa responses in  
Middle-aged adults
A representative group of 100 persons was selected for the 
functional rSBA analysis, based on the IgG concentrations. 
As expected, the majority of the participants possessed pre-
vaccination rSBA titers below the internationally accepted 
protection level of 8. MenC, MenW, and MenY-specific pre-
vaccination rSBA titers ≥8 were observed in 18, 23, and 27% 
of the middle-aged participants (Table  3). Moreover, 28  days 
post-vaccination, the vast majority of the participants possessed 
an rSBA titer ≥8, which was 94, 99, and 97% for MenC, MenW, 
and MenY, respectively. In addition, 92, 97, and 95% for MenC, 
MenW, and MenY, respectively, possessed an rSBA titer ≥128, 
the cutoff titer used for long-term protection (Table 3). One-year 
post-vaccination, protective antibody titers were still found in 
76–94% of the participants (Table 3). Surprisingly, at this time 
TaBle 1 | MenCWY and tetanus toxoid (TT)-specific IgG responses.
Menc (μg/ml) MenW (μg/ml) MenY (μg/ml) TT (iU/ml)
Pre-GMC [95% CI] 0.09 [0.06–0.11] 0.06 [0.04–0.07] 0.05 [0.04–0.06] 0.76 [0.63–0.91]
Day 7 GMC [95% CI] 0.67 [0.52–0.86] 0.13 [0.09–0.16] 0.11 [0.08–0.14] 6.81 [5.84–7.94]
Ratio day 7/pre [95% CI] 7.3 [5.9–9.0] 2.1 [1.7–2.4]****,a 2.1 [1.8–2.5]****,a 8.6 [7.4–10.6]
Number of fold change > 4 (%) 120 (58.8%) 41 (20.1%)****,a 46 (22.5%)****,a 146 (71.6%)
Day 28 GMC [95% CI] 13.03 [10.39–16.35] 2.43 [1.78–3.33] 3.49 [2.59–4.71] 13.89 [11.71–16.48]
Ratio day 28/pre [95% CI] 141 [107.5–185.1] 41.6 [31.4–55.1]****,a/*,b 67.9 [52.2–88.2]**,a 18.5 [15.5–22.1]
1 year GMC [95% CI] 2.60 [2.06–3.28] 1.99 [1.59–2.51] 1.89 [1.48–2.41] 3.51 [3.03–4.07]
Ratio day 28/1 year [95% CI] 5.0 [4.4–5.6] 1.3 [1.1–1.5]****,a 1.8 [1.6–2.2]****,a 3.9 [3.5–4.3]
The MenC, MenW, and MenY polysaccharide and TT-specific geometric mean concentrations (GMCs [95% CI], in microgram per milliliter) at the different time points pre- and post-





The MenC, MenW, and MenY-specific ratios at day 7, 28, and 1 year were compared with the Mann–Whitney U test after correction for multiple testing. Moreover, the numbers of 
persons with a fold change >4 at day 7 were compared with the Chi-square test.
FigUre 2 | MenCWY-specific IgG and IgM responses. MenC (a), MenW (B), MenY (c) polysaccharide-specific IgG, and MenC (D), MenW (e), MenY (F) 
polysaccharide-specific IgM responses pre- and post-vaccination. The lines indicate the geometric mean concentrations with 95% CI intervals. The different time 
points were compared with the repeated measured ANOVA, which was highly significant for all comparisons (p < 0.0001), after which pairwise comparisons 
between the time points were performed.
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point, slightly higher rSBA titers were observed for MenW and 
MenY compared with MenC. Moreover, a small, but significant 
negative correlation of the rSBA titer was found with age; 28 days 
post-vaccination for MenC (rho: −0.239, p: 0.017) and 1  year 
post-vaccination for MenW (rho: −0.300, p: 0.002) (Table S3 in 
Supplementary Material). No gender differences were observed 
(data not shown).
Modeling of the Protection levels  
10 Years Post-Vaccination
Using a bi-exponential decay model, the proportion of par-
ticipants with rSBA titers above the protective cutoff level of 8 at 
10 years post-vaccination was estimated to be around 40, 40, and 
60% for MenC, MenW, and MenY, respectively (Figures S2A–C 
in Supplementary Material). Moreover, 20, 20, and 40% of the 
TaBle 3 | MenCWY-specific serum bactericidal antibody responses using baby rabbit complement (rSBA).
Time point Value Menc MenW MenY
Pre- GMT 3.9 [2.9–5.3] 5.4 [3.8–7.9] 6.9 [4.5–10.4]
≥8% 18 [11.7–26.7] 23 [15.8–32.2] 27 [19.3–36.4]
≥128% 7 [3.4–13.8] 8 [4.1–15.0] 17 [10.9–25.5]
28 days GMT 1,469 [950.5–2,269] 1,771 [1,354–2,315] 1,448 [1,026–2,044]
≥8% 94 [87.5–97.2] 99 [94.6–100] 97 [91.5–99.2]
≥128% 92 [85.0–95.9] 97 [91.5–99.2] 95 [88.8–97.8]
1 year GMT 111.4 [66.6–186.4] 335.5 [236.9–475.1] 247.3 [158.1–386.7]
≥8% 76 [66.8–83.3] 94 [87.5–97.2] 86 [77.9–91.5]
≥128% 61 [51.2–70] 74 [64.6–81.6] 79 [70.0–85.8]
MenCWY-specific GMTs are presented with the [95% CI]. The percentages and  
[95% CI] of participants with an rSBA titers above 8 (cutoff for protection) and 128 (cutoff for long-term protection) are given at all time points.
GMT, Geometric mean titer.
TaBle 2 | Effect of age and gender on the MenCWY IgM responses.
group Timepoint Predicting 
variable
p-Value β coefficient R2 
model
MenC 7 days Pre-igM 0.002 0.218 0.102
age 0.001 −0.237
Gender 0.740 −0.022
28 days Pre-IgM 0.046 0.142 0.048
Age 0.018 −0.168
Gender 0.158 −0.100
1 year Pre-igM 0.000 0.292 0.106
Age 0.024 −0.158
Gender 0.426 −0.055
MenW 7 days Pre-igM 0.000 0.246 0.154
age 0.000 −0.315
Gender 0.326 −0.066
28 days Pre-IgM 0.111 0.115 0.055
age 0.002 −0.215
Gender 0.256 −0.081
1 year Pre-igM 0.000 0.307 0.148
Age 0.010 −0.176
Gender 0.045 −0.139
MenY 7 days Pre-igM 0.001 0.238 0.090
Age 0.019 −0.161
Gender 0.074 −0.123
28 days Pre-IgM 0.554 0.043 0.030
Age 0.037 −0.148
Gender 0.067 −0.131
1 year Pre-igM 0.000 0.272 0.100
Age 0.108 −0.113
Gender 0.049 −0.139
Linear regression was performed using the log-transformed IgM concentrations. Age 
was included as a continuous variable. Gender: 0 = female, 1 = male. The effects of 
age and gender were adjusted for the presence of pre-vaccination immunity (Pre-IgM), 
since pre-IgM was perceived a confounder. After correction for multiple testing, a p-value 
<0.05/9 = 0.006 was considered significant. Significant correlations are indicated in bold.
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participants were expected to possess rSBA titers above the protec-
tive cutoff level of 128 at 10 years post-vaccination for MenC, MenW, 
MenY, respectively (Figures S2D–F in Supplementary Material).
Differences in rsBa response between 
Participants with and without Pre-
Vaccination rsBa Titers
In one-fourth of the participants, a detectable pre-vaccination 
rSBA titer (rSBA ≥ 4) was observed (Figures 3A–C). Subsequently, 
we compared the vaccine response between participants being 
seropositive (rSBA ≥ 4) or being seronegative at the pre-vaccina-
tion time point (Figure 3; Table S4 in Supplementary Material). 
Similar rSBA titers were observed in both groups 28 days post-
vaccination for all meningococcal groups (Figures 3A–C; Table S4 
in Supplementary Material), indicating a robust increase in rSBA 
titer in the seronegative participants. At day 28, 89.9, 96.1, and 
93.2% of the seronegative participants showed an rSBA titer 
≥128 for MenC, MenW, and MenY, respectively, compared with 
100% of the seropositive participants (Figures 3D–F; Table S4 
in Supplementary Material). One-year post-vaccination, rSBA 
titers showed a significantly higher decay in the seronegative 
participants, reaching significance for MenW and MenY, and 
resulting in rSBA titers below the protection limit (rSBA ≥  8) 
in some participants (Figure  3; Table S4 in Supplementary 
Material).
strong correlations between the MenW- 
and MenY-specific igM responses  
and antibody Functionality
Since the rSBA titers and IgG responses for the different groups 
did not show a similar pattern, the correlations between the 
IgG and rSBA responses for the three meningococcal groups 
were determined (Figures  4A–C). A moderate correlation was 
found for MenC (28 days: rho 0.561, p < 0.001, 1 year: rho 0.548, 
p  <  0.001) (Figure  4A), whereas the correlations for MenW 
(28 days: rho 0.356, p < 0.001, 1 year: rho 0.307, p < 0.002) and 
MenY (28 days: rho 0.201, p = 0.045, 1 year: rho 0.214, p = 0.033) 
were rather low (Figures 4B,C).
This encouraged us to investigate whether MenC-, MenW-, 
and MenY-specific IgM responses could explain this low correla-
tion. Remarkably, a good correlation was found between the rSBA 
titers and the IgM responses for both MenW (28 days: rho 0.687, 
p < 0.001, 1 year: rho 0.761, p < 0.001) and MenY (28 days: rho 
0.690, p <  0.001, 1  year: rho 0.729, p <  0.001) (Figures  4E,F), 
whereas a moderate correlation was found for MenC (28 days: rho 
0.594, p < 0.001, 1 year: rho 0.529, p < 0.001) (Figure 4D). In order 
to confirm the important contribution of the IgM antibodies to the 
rSBA response, IgG was depleted in a subset of the samples varying 
in SBA titer (Figures S3A,C in Supplementary Material). MenW 
and MenY rSBA titers remained almost equal after IgG removal. 
By contrast, these rSBA titers were largely reduced after IgM 
FigUre 3 | MenCWY serum bactericidal antibody responses in participants with and without pre-vaccination rSBA titers. MenC (a), MenW (B), and MenY 
(c) specific rSBA responses at the different time points for pre-vaccination seronegative (−, red) and seropositive (+, blue) participants. The geometric mean titers 
are indicated. The seronegative and seropositive participants were compared at the different time points using the Mann–Whitney U test *p < 0.05, ***p < 0.001, 
and ****p < 0.0001. Reverse cumulative distribution graphs at day 28 and 1 year post-vaccination for MenC (D), MenW (e), and MenY (F) separated for the 
pre-vaccination seronegative (red) and seropositive (blue) participants.
FigUre 4 | Correlation between the MenCWY-specific IgG and IgM responses with the serum bactericidal antibody responses. The correlation between the MenC 
(a), MenW (B), and MenY (c) PS-specific IgG responses and the MenC (D), MenW (e), and MenY (F) PS-specific IgM responses with the rSBA responses at 
28 days and 1 year post-vaccination. Correlations were determined with the Spearman’s rho correlation test.
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depletion (Figures S3B,D in Supplementary Material), although the 
rSBA titer was mostly retained in participants with very high IgG 
concentrations. The data suggest that the protective rSBA titers are 
mediated via induction of IgM type antibodies, mainly for MenW 
and MenY.
Differential Meningococcal group-specific 
igg subclass responses
Finally, we investigated whether IgG subclass responses differed 
between the naïve (MenW and MenY) and booster (MenC) 
TaBle 4 | MenCWY-specific IgG subclass responses.
Timepoint Measurement Menc (μg/ml) MenW (μg/ml) MenY (μg/ml)
28 days IgG1 [95% CI] 3.1 [2.53–3.85] 0.4 [0.30–0.52] 2.3 [1.80–2.83]
IgG2 [95% CI] 5.1 [3.84–6.67]***,a 0.7 [0.49–1.03]***,a 1.4 [0.97–1.92]**,a
IgG1/IgG2 ratio [95% CI] 0.6 [0.48–0.81] 0.6 [0.40–0.76] 1.6 [1.19–2.21]
1 year IgG1 [95% CI] 1.0 [0.82–1.16] 0.6 [0.40–0.76] 1.6 [1.30–1.98]
IgG2 [95% CI] 1.2 [0.85–1.47] 0.8 [0.63–1.11]**,b 0.8 [0.62–1.13]***,b
IgG1/IgG2 ratio [95% CI] 0.8 [0.65–1.10] 0.7 [0.50–0.87] 1.9 [1.41–2.51]
Geometric mean concentrations [95% CI] are indicated. Meningococcal group-specific IgG1 and IgG2 responses at the different time points were compared with the  
Mann–Whitney U test.
**p < 0.01, ***p < 0.001.
aIgG2 vs IgG1 at day 28.
bIgG2 vs IgG1 at 1 year.
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responses at middle-age, as IgG subclass responses have previ-
ously been shown to affect the antibody functionality. IgG sub-
class responses were highly variable for all three groups. A slightly 
skewed IgG2 response was observed for MenC and MenW, 
whereas the response to MenY showed IgG1 skewing, as shown 
by the IgG1/IgG2 ratio (Table  4). Besides a primarily MenC-
specific IgG2 skewed response, 1 year post-vaccination IgG1 and 
IgG2 contributed equally to the IgG response, suggesting a more 
rapid decay of IgG2 than IgG1 over time (Table 4), which was not 
seen for the IgG2 skewed MenW response. Also, the IgG1 skewed 
response to MenY remained stable.
DiscUssiOn
In this study, we demonstrate that a primary tetravalent 
meningococcal vaccine conjugated to TT (MenACWY-TT) in 
middle-aged adults is highly immunogenic. The vast majority 
(94–99%) of the participants developed protective antibody 
titers against three meningococcal groups 1  month post-vac-
cination. Moreover, 1 year post-vaccination protective antibody 
titers were still found in 76–94% of the participants. This level 
of protection was slightly lower in participants without detect-
able pre-vaccination rSBA titers compared with participants 
with pre-vaccination rSBA titers. Overall, in about 40–60% of 
the participants protective antibody titers are predicted to last 
for 10  years post-vaccination. Of importance, the protective 
rSBA titers were strongly associated with the meningococcal 
group-specific IgM responses, especially for MenW and MenY. 
Remarkably, these IgM responses were still enhanced 1-year 
post-vaccination and declined with advancing age even in this 
middle-aged (50–65 years) group.
Since our study is one of the few evaluating the immunogenicity 
of the MenACWY-TT vaccine in older adults, comparative data 
are scarce. We observed similar proportions of participants with 
protective post-vaccination titers (rSBA >  128) 1  month post-
vaccination as reported by a study evaluating the immunogenic-
ity of the MenACWY-TT vaccination in persons 56–103 years of 
age, of which 67% was middle-aged (56–65), in Lebanon (23). The 
Lebanese population, however, has a different epidemiological 
background than the Dutch population, since high meningococ-
cal pre-vaccination levels were found in most Lebanese adults 
(23). Despite these differences in pre-vaccination immunity, 
comparable short-term vaccine responses were observed. In 
addition, two studies in the USA reported the immunogenicity of 
a pneumococcal conjugate vaccine with a similar composition of 
conjugated polysaccharides (the PCV13 vaccine), in older adults 
(50–69 years of age) 1 year post-vaccination (36, 37). However, 
since a large part of the older adult populations is likely to be 
primed naturally for the majority of the pneumococcal groups, 
these vaccines induced a booster response. In our study, a large 
induction of MenC-specific IgG concentrations 7 days post-vac-
cination was indicative of a booster response for MenC in most 
participants (38, 39). Since this meningococcal group induced 
robust functional antibody responses as measured by the SBA in 
our study adults, we confirmed the immunogenicity of a booster 
vaccine in middle-aged adults. In addition, we demonstrated 
robust antibody responses against the groups MenW and MenY, 
which showed a more de novo immune response in the majority 
of the middle-aged adults.
The observations of booster responses for MenC in the major-
ity of the middle-aged adults, and the more naïve responses for 
MenW and MenY are in agreement with the meningococcal 
circulation in the Dutch population in the past (17). The MenC-
specific booster response suggests long-term persistence of 
MenC-specific IgG-based memory immunity in adults, since the 
circulation of MenC was nearly eradicated after the mass vac-
cination campaign of 2002 (40). These memory cells may reside 
in the bone marrow and do not necessarily correlate with serum 
antibody levels (41, 42). The currently ongoing circulation of 
MenW and MenY might explain the high pre-vaccination SBA 
titers and IgM concentrations that were found in a small part of 
the participants, suggesting prior exposure (18, 21). However, 
meningococcal carriage studies in older adults are lacking to 
confirm our results.
We observed highly variable IgG subclass responses in the 
middle-aged adults for all meningococcal groups, a common 
finding after conjugate-carrier vaccination in adults (43–45). 
This may be explained by multifactorial causes such as host-
specific contacts during life, chemical antigen characteristics 
as well as the age of the vaccinees (45, 46). Clearly, this would 
require further study. In this study, MenC- and MenW-specific 
IgG responses showed a skewing toward the IgG2 subclass, 
whereas IgG1 skewing was seen for MenY. Since, in general, IgG1 
shows better complement binding compared with IgG2 (47), the 
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MenY-specific IgG1 skewed response could be considered to be 
more functional. However, we found the weakest correlation 
between the total IgG concentrations and rSBA titers for MenY, 
which does not support the higher functionality of the MenY-
specific IgG response in bacterial killing. Therefore, in adults, the 
exact roles of the IgG subclass responses in antibody functionality 
remains incompletely understood.
Remarkably, rSBA titers were largely determined by the group-
specific IgM response, especially for MenW and MenY, since 
depletion of IgG did not significantly reduce the rSBA response, 
whereas IgM depletion did. IgM is known to be highly effective 
in complement binding (48) and found to be essential in the 
functionality of the pneumococcal antibody response (12). We 
here observed a negative correlation between the IgM response 
post-meningococcal vaccination and age in middle-aged adults, 
within a relatively small age range of 15 years. Therefore, we do 
expect a reduced functional meningococcal antibody response 
after primary immunization or even infection in the elderly. 
This expectation is strengthened by previous observations of an 
inverse correlation between serum IgM as well as IgM + B-cells 
and age (12, 46, 49–51). It may be possible to extrapolate to other 
primary bacterial infections and vaccinations in the elderly. 
Therefore, we propose to measure IgM responses, next to IgG, 
following primary bacterial vaccinations in middle-aged and 
elderly populations. Remarkably, participants possessing very 
high pre-vaccination IgG concentrations tended to show lower 
IgM concentrations post-vaccination and did not show a decrease 
in rSBA titer after IgM depletion. This finding suggests that the 
antibody functionality is reliant on high levels of IgG during clear 
booster responses. Since IgG responses may be less affected dur-
ing the aging process, functional antibody responses develop after 
additional booster vaccinations during old age. Furthermore, 
unlike often reported for other pathogens (52), no clear gender 
differences were observed in the vaccine response in this age 
group.
In addition, we show high pre-vaccination TT-specific IgG 
concentrations in the majority of the middle-aged adults, which 
were highly boosted by the MenACWY-TT vaccination. This 
finding is different to the study in the Lebanese population, 
who possessed very low pre-vaccination TT-specific antibody 
levels that were only minimally boosted by the vaccination (23). 
This difference in pre-vaccination immunity may be caused by 
higher frequencies of TT booster vaccinations in the Dutch 
adults due to traveling or by higher frequencies of childhood TT 
vaccinations in the Netherlands. Previous surveillance studies 
also revealed relatively high TT antibodies in Dutch older adults 
(53). Since the TT carrier protein in this conjugated meningo-
coccal vaccine is added to induce T-cell help in response to the 
meningococcal polysaccharides in order to induce long-term 
immunity and memory B-cell formation (54), the amount of 
T-cell help in our study may be different from the Lebanese 
population.
This study has important strengths, such as the use of a mul-
tivalent vaccine, containing antigens that induced both booster 
and naïve responses in the same participant. This allowed us to 
compare the immunogenicity of naïve and booster responses 
within the same group of middle-aged adults. Moreover, the blood 
sampling at 7 days post-vaccination strengthened our assumption 
of a general booster response for MenC and more naïve responses 
for MenW and MenY. In addition, the vaccine immunogenicity 
was based on an internationally accepted protective threshold in 
antibody functionality. Although we only measured this antibody 
functionality in a selection of 100 participants, this selection was 
representative for the entire cohort, since two independent selec-
tions of 50 participants, based on varying IgG responses from low 
to high concentrations, showed similar rSBA results. Finally, our 
data add clinically relevant information about the immunogenic-
ity of the MenACWY-TT vaccine in middle-aged adults, which 
could be used to cease the currently ongoing MenW outbreak 
or to decrease the vulnerability of the future elderly population 
for new outbreaks. However, our study was limited in predicting 
long-term protection due to the short follow-up period. Using the 
bi-exponential decay model, we estimate that about 40–60% of our 
cohort may still be protected 10 years post-vaccination. However, 
this model needs to be validated by additional sampling of the 
participants several years post-vaccination. These additional 
samples are essential to determine the exact beneficial effects of 
vaccination at middle age for upholding memory immunity in the 
elderly.
To conclude, primary immunization with a tetravalent menin-
gococcal vaccine, which contains antigens for which no or (very) 
low pre-vaccination immunity exists, was highly immunogenic 
in middle-aged adults. One-year post-vaccination protective 
antibody titers were still found in the vast majority of the par-
ticipants. Future follow-up studies can determine the long-term 
protection of this meningococcal vaccination in elderly partici-
pants, although long-term protection is predicted in about half of 
the participants using bi-exponential decay modeling. Moreover, 
IgM was found essential in the antibody functionality against 
the new antigens and showed a decrease with advancing age. 
These findings support the suggestion that immunization against 
de novo antigens should be implemented before reaching old 
age. In short, our results imply that enhancing immunological 
memory by primary vaccination of middle-aged persons is feasi-
ble and provides a basis for novel strategies to extend protective 
immunity until old age.
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